Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Comapring Luteal Phase Support in IVF Patients Who Are at High Risk for Developing OHSS

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02827656
Recruitment Status : Unknown
Verified June 2016 by Meir Medical Center.
Recruitment status was:  Not yet recruiting
First Posted : July 11, 2016
Last Update Posted : July 12, 2016
Sponsor:
Information provided by (Responsible Party):
Meir Medical Center

Brief Summary:
The purpose of this study is to compare two luteal support protocols in In vitro fertilization patients (IVF) and are at risk of developing ovarian hyperstimulation syndrome (OHSS). We would like to determine whether luteal Decapeptyl on days 3, 6,9 post ovulation triggering is as good as low dose hCG on day 3 post triggering..

Condition or disease Intervention/treatment Phase
Infertility Drug: Decapeptyl Drug: hCG luteal support Not Applicable

Detailed Description:

This is randomized clinical trial studying two luteal support protocols of In vitro fertilization patients (IVF) treated by a GnRH antagonist (GnRH ant) protocol and are at risk of developing ovarian hyperstimulation syndrome (OHSS). The randomization procedure will be performed by a third party in the hospital by using a randomization table: patients fulfilling the inclusion and exclusion criteria and giving their informed consent will be randomized into one of two arms. This study does not include any intervention affecting the ovarian stimulation and is solely intended to test the post ova pickup period.

One arm will be treated by luteal Decapeptyl on days 3, 6,9 post ovulation triggering. Second arm will be treated by low dose hCG on day 3 post triggering. All patients to be recruited are treated for acceptable IVF indications in Meir medical center (MMC) and their registry is computerized in the general system of MMC. For the purpose of the study we will use the only the data of patients recruited to the study and were giving their informed consent. Each patient recruited will have a unique study identity (ID) . The patients' information will be pooled from the computerized file into an Excel spread sheet: in this Excel file the names will be erased and only the unique study ID will appear. The information regarding the coding key will be kept as a hard copy in a locked room inside the IVF unit in a special study folder. The study was approved by MMC institutional Helsinki board.

The data retrieved for each patients is not unique for the study but includes the basic variables monitored in every IVF cycle : Estradiol serum levels (E2), Progesterone serum levels (P), number of follicles as counted by trans-vaginal ultrasound, endometrial thickness as measured by trans-vaginal ultrasound, Follicle stimulating hormone (FSH) dosing, number of stimulation days, number of eggs retrieved, fertilization rate, blastulation rate, number of embryos transferred, embryo quality, positive pregnancy test, implantation rate, presence of a clinical pregnancy, presence of OHSS. Since these are mandatory variables in the treatment we do not expect any missing data. In addition to these mandatory data the study patients will be performing two additional blood tests on day 3 post ovum pickup and on the transfer day itself (day 5 post ovum pickup) including Estradiol serum levels (E2) and Progesterone serum levels (P).

Outcome measures: Day of transfer Progesterone serum levels, OHSS rate, implantation rate, clinical pregnancy rate.

Sample size calculation based on Kol S et al 2015, regarding the day of transfer Progesterone level (pooled standard deviation: 40nmol/L), alpha of 5%, 80% power, then a non-inferiority study will require 22 patients in each group and a total of 44 patients. Once including an expected 10% chance of freeze all in this population we will include 50 patients.

Statistical analysis: Analysis of data was performed using the SPSS 23.0 computer package (SPSS Inc., Chicago, IL). Normally distributed data were analyzed by student t test . χ2 or Fisher's exact test will be used for comparisons of rates and proportions. All P values were tested as two-sided and considered significant at less than 0.05.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 50 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Luteal Phase Support With Human Chorionic Gonadotropin (hCG) Versus Gonadotropin Releasing Hormone (GnRh) Agonist in IVF Patients Who Are Risk for Developing OHSS
Study Start Date : August 2016
Estimated Primary Completion Date : August 2017
Estimated Study Completion Date : December 2017

Arm Intervention/treatment
Experimental: Decapeptyl support
S.C single luteal Decapeptyl 0.1 mg on days 3, 6,9 post ovulation triggering
Drug: Decapeptyl
luteal support as described and vaginal progesterone 200 mg 3 times a day

Active Comparator: hCG luteal support
S.C single luteal S.C recombinant hCG 50 micrograms on days 3 ovulation triggering
Drug: hCG luteal support
luteal support as described and vaginal progesterone 200 mg 3 times a day




Primary Outcome Measures :
  1. Progesterone serum level [ Time Frame: day 5 post ovum pickup ]

Secondary Outcome Measures :
  1. positive pregnancy test [ Time Frame: 9-12 days post embryo transfer ]
  2. implantation rate [ Time Frame: 30-33 days post embryo transfer ]
  3. clinical pregnancy rate [ Time Frame: 30-33 days post embryo transfer ]
    clinical pregnancy is considered as a presence of a viable embryo (heart activity present)



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 40 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • IVF treatment
  • GnRH antagonist protocol
  • GnRH agonist triggering of ovulation
  • High risk for OHSS as expressed by either E2 serum level >2500 pg/ml

Exclusion Criteria:

  • background maternal morbidity
  • Any protocol other than GnRH antagonist protocol
  • hCG triggering of ovulation
  • E2 serum level >4500 pg/ml
  • Aspiration of >25 ova
  • Embryo transfer prior to day 5

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02827656


Contacts
Layout table for location contacts
Contact: Anat Klement, MD anat.klement@gmail.com
Contact: Helsinki Committee MMC 97297471588

Sponsors and Collaborators
Meir Medical Center
Investigators
Layout table for investigator information
Principal Investigator: Amir Wiser, MD MMC
Publications:

Layout table for additonal information
Responsible Party: Meir Medical Center
ClinicalTrials.gov Identifier: NCT02827656    
Other Study ID Numbers: 056-16MMC
First Posted: July 11, 2016    Key Record Dates
Last Update Posted: July 12, 2016
Last Verified: June 2016
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Keywords provided by Meir Medical Center:
Fertilization in vitro
Luteal Phase
ovarian hyperstimulation syndrome
Additional relevant MeSH terms:
Layout table for MeSH terms
Infertility
Triptorelin Pamoate
Luteolytic Agents
Contraceptive Agents, Female
Contraceptive Agents
Reproductive Control Agents
Physiological Effects of Drugs
Contraceptive Agents, Hormonal
Antineoplastic Agents, Hormonal
Antineoplastic Agents